Phaseline

Companies › TaiMed Biologics

TaiMed Biologics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Infectious disease; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TMB-365
HIV post-attachment inhibitor; monoclonal antibody that binds to CD4 receptor
CD4Phase 2HIV -1 InfectionMay 2027
TMB-380
Broadly neutralizing antibody (bNAb) against HIV; monoclonal antibody that binds to HIV en
ENVPhase 2HIV -1 InfectionMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07215468TMB-365Phase 2HIV -1 InfectionInfectious diseaseMay 2027
NCT07215468TMB-380Phase 2HIV -1 InfectionInfectious diseaseMay 2027

Targets

CD4 (1) ENV (1)

Companies with the same targets

Gilead Sciences GSK PolTREG

Companies built like this

Suzhou HepaThera Biotech Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.